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ABSTRACT

Chronic Kidney Disease (CKD) is currently the ninth leading cause of death in the
United States, and despite the favorable outcomes reported in previous studies, mortality
rates for CKD have yet to show improvement. The purpose of this study was distinguish
between the different strategies used to treat CKD as perceived by renal practitioners. It
is hypothesized that the lack of improvement in mortality rates may be attributed to the
lack of cardiovascular protection.
This study was a descriptive qualitative study conducted from February 5th, 2019 to
March 21st, 2019, following the completion of a pilot study. Participants completed a
survey with questions related to their experience working with CKD patients and the
current nutrition education provided to patients at dialysis units. In this study, renal
practitioners from 250 dialysis units in continental states of the United States were
contacted to gather information on their perspectives in relation to nutrition education
in dialysis units. The sample included registered dietitians (n=63), registered nurses
(n=3) and certified nurse assistants (n=2). The original sample consisted 76 participants,
of which 68 met the criteria of: currently working with dialysis patients and not have
participated in the pilot study. Descriptive data was analyzed using software Minitab
and Microsoft Excel was used to create visual representation of the responses.

Findings suggest that there is indeed a lack of focus on the quality over quantity of
nutrients when providing nutrition education to CKD dialysis patients and this may
ii

translate into the negative outcomes commonly observed in relation to cardiovascular
health and subsequent mortality rates in the CKD population. Current guidelines are
targeting the state of uremia in dialysis patients, putting a larger emphasis on the
quantity rather than the quality of nutrients, contributing to a harmful state for these
patients’ cardiovascular system.
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CHAPTER I
INTRODUCTION
Statement of the Problem
The obesity pandemic has brought an increased prevalence of chronic diseases,
such as type II diabetes mellitus and hypertension, which are the most common causes
of chronic kidney disease (CKD) (Hruby & Hu, 2015; Hossain, Kawar, & El Nahas,
2007; Hurt, Kulisek, Buchanan, & McClave, 2010; Mitchell, Catenacci, Wyatt, & Hill,
2011). A healthy kidney is able to remove all metabolic by-products via urine and it
also participates in hormone production, maintaining the state of homeostasis in the
body. When kidneys are damaged, toxins begin to build up due to the inability to
effectively filter the blood, causing further decline in kidney function. Kidney disease,
which represents the ninth leading cause of death in the US (Xu, Murphy, Kochanek,
& Bastian, 2018), is a degenerative condition characterized by a gradual decline in
kidney function and structural changes; when these abnormalities in function and
structure persist for longer than three months, this disease is classified as CKD
(Kidney Disease Improving Global Outcomes, 2013). Chronic kidney disease is
asymptomatic, thus early screening and detection, as well as adherence to prescribed
interventions, are the most effective ways of slowing or avoiding the progression of
the disease (National Kidney Foundation, 2019b).
Uremia is a condition characterized by abnormal levels of waste products in
the blood. Many of the complications experienced by the CKD population are
1

attributed to occurrence of uremia (Meyer & Hostetter, 2014). Dialysis is unable to
remove retained waste products as effectively as healthy kidneys would, therefore
current nutritional guidelines for CKD are focused on improving the state of uremia
observed in individuals with CKD. However, current guidelines are not effective at
providing the cardiovascular protection this population is in desperate need for, as they
focus more on restrictions of specific nutrients as opposed to the potential impact of
quality over quantity of nutrients consumed.
The screening process for CKD includes identifying high-risk patients, such as
those with Type 1 or 2 Diabetes Mellitus, hypertension, cardiovascular disease and/or
with a family history of CKD, and followed by assessing urinary albumin excretion
and calculating estimated glomerular filtration rate (eGFR) from stable serum
creatinine levels. Estimated GFR can be calculated using either the Modification of
Diet in Renal Disease (MDRD) Study Equation or the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation (Levey et al., 2009; Stevens et al.,
2007). Other labs used to confirm CKD diagnosis are blood urea nitrogen (BUN),
hematocrit and hemoglobin. BUN measures the amount of waste products in the urine,
in the form nitrogen and urea. Nitrogen is a by-product of protein metabolism, and
urea is a waste product formed by the liver from available ammonia and carried by the
blood to the kidneys for excretion. Hematocrit is measured to determine the proportion
of the blood that consists of red blood cells. Hemoglobin is measured to check on the
production of erythropoietin (EPO) hormone. EPO is secreted by the kidneys in
response to low oxygen in order to stimulate red blood cell production. The
2

intervention prescribed following a CKD diagnosis depends on the severity of the
disease at the time of detection but it generally includes diet modification, prescription
of pharmaceuticals and at later stages, dialysis or kidney transplantation.
Regardless of etiology, the loss of kidney function in CKD disrupts
homeostasis in the body. The albumin creatinine ratio (ACR) and the eGFR are
mechanisms used to grade the stage of CKD. Albumin is a protein normally found in
the blood and creatinine is the product of muscle metabolism. ACR varies among the
stages of CKD. Estimated GFR is a measure used to describe the flow rate of filtered
fluid through the kidney. Normal kidney function is characterized as an eGFR ≥90
mL/min/1.73m2. Individuals with normal GFR but with another indicator of kidney
damage are diagnosed as stage one. Stages 2 through 5 are diagnosed based on eGFR,
as summarized in Table 1. When the eGFR is less than 60 mL/min/1.73 m2, certain
disruptions in homeostasis begin to occur. Phosphorus retention occurs due to reduced
urinary phosphorus excretion. This results in decreases in serum calcium levels due to
the binding of phosphorus to calcium. To return to homeostasis, the parathyroid gland
releases parathyroid hormone (PTH) which releases calcium from bone and stimulates
renal tubule reabsorption of calcium. PTH also decreases renal phosphorus
reabsorption and increases excretion. Thus, serum calcium and phosphorus return to
normal at the expense of a higher serum PTH. With every decrease in eGFR, the
process repeats itself. Eventually the eGFR gets so low that hyperphosphatemia
impairs gut absorption of calcium leading to hypocalcemia, while PTH continues to
rise (Martin & Gonzalez, 2007).
3

Table 1. Stages of CKD
Stages of CKD

GFR
(mL/min/1.73m2)
≥90

Stage 1

Kidney damage with normal kidney function

Stage 2

Kidney damage with mild loss of kidney function

Stage 3

Moderate loss of kidney function

30-59

Stage 4

Severe loss of kidney function

15-29

Stage 5

Kidney failure, or ESRD

60 – 89

<15

Increased serum phosphorus also suppresses the synthesis of 1,25(OH)2
vitamin D3, which in turn decreases bone formation. Increased PTH, while bad for
bone, will stimulate synthesis of 1,25(OH)2 vitamin D3 by the failing kidneys in an
attempt to normalize secretions. Metabolic acidosis develops because the failing
kidneys cannot keep up with the excretion of the metabolically generated hydrogen
ions. The excess hydrogen ions are buffered by bicarbonate, but they also make their
way into bone cells causing the release of calcium ions, weakening bone even more.
Thus, the combination of bone reabsorption from too much PTH, the buffering of
hydrogen ions, and the decreased bone formation due to low 1,25(OH)2 vitamin D3,
results in the development of renal osteodystrophy, the bone malformation aspect of
CKD-Mineral and Bone Disorder (CKD-MBD) (Martin & Gonzalez, 2007).
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It is known that when calcium-phosphorus product exceeds the solubility
product, it may contribute to crystal precipitation in the vasculature (Yamada &
Giachelli, 2016). However, klotho and FGF23 are also thought to play a key role in
vascular calcification. There is growing evidence gathered from animal experiments
that demonstrates that a decrease in klotho levels can cause vascular calcification,
cardiac hypertrophy, cardiac fibrosis (Lu & Hu, 2016). The changes in metabolic
pathways of bone minerals, the interruption in calcium and phosphate homeostasis,
and the vascular calcification observed in CKD patients in relation to these alterations
are collectively known as CKD-MBD (Kidney Disease Improving Global Outcomes,
2017).
Mineral and bone disorders are an inevitable consequence of CKD. While
many approaches are taken to treat CKD-MBD, no data currently exists stating its
exact prevalence. Research has shown that intervention in the form of intense nutrition
education can significantly improve clinical outcomes as well as improve quality of
life (Duff & Chawke, 2017; Ebrahimi, Sadeghi, Amanpour, & Dadgari, 2016;
Karavetian, de Vries, Elzein, Rizk, & Bechwaty, 2015; Karavetian, Elzein, Rizk, Jibai,
& De Vries, 2016).
Specific Aims
The focus of this thesis is to distinguish between the different strategies used to
treat Chronic Kidney Disease- Mineral Bone Disorder, the perceptions across

5

disciplines and barriers to maintaining mineral homeostasis during dialysis. The
specific aims for this study are:
Aim 1: To explore the current barriers perceived by renal practitioners
at dialysis units when addressing the imbalance of minerals that manifests as a
result of CKD.
Aim 2: To identify the nutrition education techniques that are used
most frequently in dialysis units and the main concepts discussed in reference
to bone mineral metabolism.
Aim 3: To understand what specific nutrients healthcare practitioners
target when providing nutrition education to manage CKD-MBD.
Aim 4: To determine the amount of time that is being devoted to
nutrition education by different renal practitioners and to distinguish how
nutrition information is being delivered across disciplines.

6

CHAPTER II
LITERATURE REVIEW
Epidemiology of Chronic Kidney Disease
Prevalence and stages of chronic kidney disease
Approximately 37 million American adults suffer from chronic kidney disease
(CKD). The national prevalence for chronic kidney disease stages 1-4 is estimated to
be 15% according to data from 2013–2016 National Health and Nutrition Examination
Survey (NHANES). It is estimated that one in two people with severely decreased
kidney function and 96% of people with kidney damage or mild loss of kidney
function are undiagnosed, while many others are unaware of their increased risk for
this disease (Center for Disease Control and Prevention, 2017; 2019). Data from
NHANES 1999-2014 indicate that about 2.7% of individuals diagnosed with kidney
disease reported being aware of their condition in 2012, and about 2.8% in 2014. If
left untreated, kidney disease can lead to death. As of 2016, this progressive and
chronic condition reported a national death rate of 13.1 per 1000 deaths (Center for
Disease Control and Prevention, 2018).
The estimated glomerular filtration rate (eGFR) measurement is used to
evaluate kidney function and is calculated by using a GFR estimating equation to
derive eGFR from serum creatinine (eGFRCr). (Kidney Disease Improving Global
Outcomes, 2013; Levey et al., 2009; Stevens et al., 2007). The most commonly used
GFR estimating equations are Modification of Diet in Renal Disease (MDRD) Study
7

Equation or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation (Table 2) (Levey et al., 2009; Stevens et al., 2007).

Table 2. Glomerular filtration rate equations
eGFR (ml/min/1.73m2) =
175 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African
American)
CKD-EPI eGFR (ml/min/1.73m2) =
creatinine 141 x min (Scr/k, 1)α x max (Scr/k, 1)-1.209 x 0.993Age x (1.018 if female) x
(1.159 if African American)
CKD-EPI eGFR (ml/min/1.73m2) =
133 x min (Scys/0.8, 1)-0.499 x max (Scys/0.8, 1)-1.328 x 0.996Age x (0.932 if
Cystatin
female)
*Scr (standardized serum creatinine) = mg/l
*Scys (standardized serum cystatin C) = mg/l
*k is 0.7 for females and 0.9 for males,
*α is -0.329 for females and -0.411 for males
MDMR

Current guidelines favor the use of the CKD-EPI equation as current evidence
has shown increased accuracy, particularly at higher GFR (Kidney Disease Improving
Global Outcomes, 2013). Evidence also shows that estimating GFR from cystatin C
(eGFRCys) instead of serum creatinine can be a more powerful indicator of GFR, yet
there is a lack of evidence showing that the favorable outcomes of using this
expensive method outweighs the burden of cost (Florkowski & Chew-harris, 2011).
Current guidelines recommend using eGFRCys only in cases where cystatin C has
being measured or when required as a confirmatory test for patients found to have
eGFRCr of 45-59 ml/min per 1.73m2 but absent of any other indicator of kidney
8

damage (Kidney Disease Improving Global Outcomes, 2013). Recent studies are
exploring the effectiveness of new GFR estimating equations, such as the LundMalmo equation or Full- Age Spectrum equation, but their use has not yet being
validated to replace current recommendations (Nyman et al., 2014; Pottel et al., 2016).
Once GFR has been determined, the measurement of eGFR is used to classify
the severity of the loss of kidney function is categorized into five stagesas summarized
in Table 1. Individuals are considered to have reduced kidney function when
diagnosed as stage 3 and often require the use of renal replacement therapy (RRT), or
dialysis, to mimic the blood filtering functions of the kidneys when stage five is
reached (Kidney Disease Improving Global Outcomes, 2013).
Another important measurement used to confirm the diagnosis of kidney
disease by assessing kidney damage is the albumin to creatinine ratio (ACR). Albumin
is a protein normally found in the blood. When kidneys are healthy, this
macromolecule is unable to pass into the urine. When there is kidney damage, the
glomerular permeability is altered resulting in abnormal urinary protein excretion and
accumulation of waste products in the blood. For example, creatinine, a waste product
of muscle metabolism, is filtered effectively by a healthy kidney but not when kidney
damage is noted. Persistent protein leakage is associated with increased risk of CKD
progression (Cravedi & Remuzzi, 2013). The ACR measurement assesses the urinary
albumin excretion and it is used for the classification of three albuminuria categories:
<30 mg/g classified as mild, 30-300 mg/g as moderate, and >300 mg/g as severe
9

(Kidney Disease Improving Global Outcomes, 2017). KDIGO 2012 guidelines
recommend that CKD should be classified based on etiology, stages of GFR and
categories of albuminuria. The nutrition and medical intervention vary in accordance
to the stages (Kidney Disease Improving Global Outcomes, 2013).
Unfortunately, although kidney transplant is an option for patients with ESRD,
not all ESRD patients are suitable candidates for transplantation. Healthcare
practitioners discuss eligibility with patients and educate them about renal
transplantation when they are approaching ESRD or in some instances, are already at
this stage. The availability of the use of transplantation as a kidney replacement
therapy is determined by the perceived risks of transplantation relative to the risks of
not receiving a transplant. Some of the factors to be considered are age, psychosocial
status, weight status, perceived adherence and tobacco use (“KDIGO Clinical Practice
Guideline on the Evaluation and Management of Candidates for Kidney
Transplantation Public Review Draft,” 2018).
Risk factors and comorbidities of chronic kidney disease
Risk factors for CKD can be categorized into two groups: modifiable risk
factors (such as lack of physical activity, poor diet, tobacco use, exposure to toxic
substances and obesity), and non-modifiable (such as age, gender, low-birth weight,
genetics, socioeconomic status and family history). Conditions such as diabetes
mellitus (Type 1 and 2) and hypertension result in an increase in risk for developing
CKD. The risk for developing ESRD increases by 12-fold in diabetics and 7-fold in
10

hypertensive patients (Kazancioǧlu, 2013). In addition, not only is obesity a risk factor
for CKD, but also for diabetes, hypertension, and cardiovascular diseases
(Kazancioǧlu, 2013). Findings suggests that obesity has an impact in the pathogenesis
of CKD regardless of the presence of diabetes mellitus and/or hypertension (Garland,
2014). The growing concern for rapidly increasing rates of chronic disease such as
CKD, diabetes and hypertension is, in part, associated with the recent rise in obesity
rates (Hruby & Hu, 2015; Hossain, Kawar, & El Nahas, 2007; Hurt, Kulisek,
Buchanan, & McClave, 2010; Mitchell, Catenacci, Wyatt, & Hill, 2011).

Figure 1. Comorbidities versus risk factors for CKD

Diabetes Mellitus Type 1 and Type 2 not only represent strong risk factors for
CKD but they are also conditions commonly found to coexist with CKD. A report
released by the Centers for Disease Control and Prevention (CDC) in 2015 estimates
that about 30.3 million Americans (about 9.4% of the US population) have diabetes
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and 84.1 million have pre-diabetes, a condition that acts as a precursor for Type 2
diabetes mellitus. National Health and Nutrition Examination Survey (NHANES) data
from 1999-2006 demonstrated that approximately 39.6% of people with diagnosed
diabetes suffer from CKD, in contrast to 41.7% with undiagnosed diabetes, 17.7%
with prediabetes and 10.6% of people without diabetes (Plantinga et al., 2010).
Hypertension, a condition characterized by elevated blood pressure, also
represents a strong risk factor and common coexisting condition for CKD. According
to the CDC, about one in every three adults in the United States suffer from high blood
pressure and only about half of them have their condition under control (Center for
Disease Control and Prevention, 2016; Nwankwo, Yoon, Burt, & Gu, 2013). In 20132014 the prevalence for self-reported hypertension in CKD population was reported to
be 59.1% (Center for Disease Control and Prevention, n.d.). Uncontrolled
hypertension represents a risk factor for CKD and can also accelerate the deterioration
of kidney function; concurrently, CKD is also found to be a risk factor for
hypertension due to the effect of the decline in kidney function in blood pressure
levels (Judd & Calhoun, 2015). Blood pressure is poorly controlled by individuals
with CKD, despite of the growing evidence on the effects of uncontrolled blood
pressure in the progression of CKD (Lee et al., 2017). The U.S. Renal Data System
(USRDS 2002) reported that CKD patients are more likely to die than to reach endstage renal disease (ESRD), and majority of those deaths are attributed to
cardiovascular complications (Snyder, J.J., & Collins, 2017; U.S. Renal Data System:
USRDS 2002 Annual Data Report, Bethesda MD, 2002).
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In spite of hypertension and diabetes mellitus being the major correlates to
CKD, there are other important risk factors to consider. CKD has been linked to
genetic and environmental factors such as genetic composition, family history, gender,
acute kidney injury and toxins. A study conducted by Kottgen et al. (2009) explored
the association between genetics and the pathogenesis of kidney disease. Results
suggested that genetics can increase the susceptibility for decreased kidney function
by passing down mutations, or errors, in the gene code affecting the process by which
Tamm-Horsfall proteins are made within the kidneys. However, there is a need for
further research in the area of genetics to provide a better understanding of the genetic
component of CKD.
Susceptibility to developing CKD is not only thought to be affected by
genetics, but also by family history, age and gender. CKD is hereditary, hence the
importance of family history when dealing with this population. Chances of having
CKD also increase with age over 60. A study by Suleymanlar et al. (2011) conducted
in Turkey reported the odds ratios of CKD as 1.45-2.18 for every 10 year increase in
age and reported the CKD odds ratios as 1.54 for females over males (Süleymanlar et
al., 2011). According to the CDC, CKD is more prevalent in females than males (16%
vs 13%), but males are 64% more likely than females to develop ESRD (Center for
Disease Control and Prevention, 2017). This statement is corroborated with an article
by Goldberg, and Krause in which the researchers explain the differences in
progression of the disease among genders and states that despite the increased
prevalence of CKD for women, CKD in men tends to progress more rapidly giving
13

males a higher prevalence for ESRD as well as mortality rate from this condition
(Goldberg & Krause, 2016). Physical injuries, infections, drugs or toxins are all
capable of injuring the kidneys and speed up the disease if already present (Center for
Disease Control and Prevention, 2017).
Another comorbidity of CKD is anemia. One of the primary causes may be the
amount of iron lost during hemodialysis (Besarab & Ayyoub, 2007) . The prevalence
for anemia in patients with CKD is estimated to be approximately 8.4% in stage 1 up
to the rate of 53.4% in stage 5. Prevalence of anemia among people without CKD is
approximately 6.3% (Stauffer & Fan, 2014). Another factor contributing to anemia in
this population is the diminished erythropoiesis resulting from kidney damage.
Erythropoietin is a hormone secreted by the kidneys in response to a low oxygen level
in order to stimulate red blood cell production. Kidney damage compromises the
production of erythropoietin and can contribute to the anemia in chronic kidney
disease (Stauffer & Fan, 2014). An imbalance in iron homeostasis also contributes to
the manifestation of anemia in CKD. This imbalance is partly due to the increased iron
losses resulting from dialysis and the abnormal levels of hepcidin hormone secretion.
Hepcidin is a hormone secreted by the liver and its main function is to maintain
systemic iron homeostasis. It does this by binding an inducing degradation ferroportin
(an iron exporter) on duodenal enterocytes, reticuloendothelial macrophages, and
hepatocytes to inhibit iron entry into the plasma. Data suggests that the excess
hepcidin observed in CKD patients may contribute to the impaired dietary iron
absorption and reticuloendothelial cell iron blockade in this population (Babitt & Lin,
14

2010; Courselaud et al., 2002; Krause et al., 2000; Nemeth et al., 2004; Park, Valore,
Waring, & Ganz, 2001). Course of treatment for anemia in CKD population include
iron supplementation, erythropoietin stimulating agents or even blood transfusions
(Lawler et al., 2010; Stauffer & Fan, 2014). Results from a retrospective cohort study
suggest that patients are more likely to initiate iron supplementation therapy (30.8%)
and blood transfusion (16.1%) than they are to receive erythropoietin stimulating
agents (7.1%) (Lawler et al., 2010).

Despite the etiology, implementing proper

screening techniques for identifying individuals at risk for CKD can result in
prevention or delayed progression of CKD and its comorbidities.
Chronic Kidney Disease-Mineral and Bone Disorder
Pathophysiology of chronic kidney disease-mineral bone disorder
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is
characterized by disturbances in mineral and bone metabolism. This includes
abnormalities in the metabolism of calcium, phosphorus, parathyroid hormone (PTH),
and vitamin D. This can lead to abnormalities in bone turnover, mineralization,
volume, linear growth, strength and calcification of vascular or other soft tissue
(Kidney Disease Improving Global Outcomes, 2017). The progressive calcitriol
(1,25(OH)2 vitamin D3) deficiency that is often manifested by Stage 2 of CKD was
thought to be the first clinical indicator of Mineral Bone Disease (Levin et al., 2007).
Current research suggests that the pathophysiology of CKD-MBD begins with
alterations of the hormone Fibroblast Growth Factor-23 (FGF-23) and its co-receptor
15

α-klotho which occur prior to the decrease in serum active vitamin D levels. FGF23 is
a hormone synthesized by osteocytes and osteoblasts (bone cells). Findings suggest
that FGF-23 could be a potential cause of the CKD associated vitamin D deficiency by
suppressing renal 1α-hydroxylase expression in proximal tubules. 1α-hydroxylase is
an enzyme that catalyzes the activation of 25-hydroxyvitamin D to 1,25(OH)2 vitamin
D3 (Hruska, Seifert, & Sugatani, 2016).
The Chronic Renal Insufficiency Cohort study had similar findings about the
way FGF23 suppresses 1α-hydroxylase leading to vitamin D deficiency observed in
early stages of CKD (Isakova et al., 2011). The resulting low levels of 1,25 (OH)2
vitamin D3 from over production of FGF23 affects parathyroid hormone (PTH)
secretion. Low levels of vitamin D lead to the inability to obtain the proper amount of
calcium from their diet by decreasing its gastrointestinal (GI) absorption, and also an
increase in PTH secretion in an attempt to increase calcium levels. Elevated PTH
levels will promote vitamin D activation in the proximal tubules of the kidneys and
osteoclast differentiation and bone resorption, mobilizing calcium (along with
phosphorus) from the bones (Figure 1). PTH will also increase calcium resorption in
the GI tract. In spite of this indirect relationship between FGF23 and increased PTH
secretion, there is a feedback loop representing a direct connection between FGF23
and PTH. The production of FGF23 acts like a brake pedal by directly decreasing PTH
synthesis and secretion in the parathyroid gland (Komaba & Fukagawa, 2010).

16

Figure 2. Metabolic changes in state of hypocalcemia
1) The parathyroid gland protects the body against hypocalcemia by constantly
regulating serum calcium levels. In state of hypocalcemia, the parathyroid
releases parathyroid hormone (PTH) and additional PTH is synthesized 2) PTH
acts on the bones and mobilizes calcium to increase serum calcium levels 3)
PTH stimulates calcium resorption and vitamin D activation in the kidneys 4)
Released vitamin D then facilitates calcium resorption in the gastrointestinal
tract (GI) 5) Endocrine feedback loop: PTH drives the activation of vitamin D,
and the active vitamin D then shuts off PTH production.

FGF23 is synthesized in response to elevated phosphate levels leading to
increased phosphorus excretion and decreased GI absorption (Hruska et al., 2016). As
a result to this previously explained mechanisms, phosphorus and PTH levels remain
17

normal until later stages of the disease. α-Klotho acts as a cofactor in the regulation of
FGF23 signaling, thus working together in the pathway to provide mineral ion
homeostasis. As the disease progresses, klotho deficiency develops and this not only
leads to hyperphosphatemia but it also deactivates the feedback loop with the
parathyroid gland that brakes the production of PTH, therefore leading to
overproduction of PTH and increased calcium and phosphorus excretion from the
bones (Hruska et al., 2016).
Another factor that is involved in the progression of CKD is high phosphorus
consumption (Figure 2). In rodents, increased renal tubular damage is positively
associated with increased phosphate excretion (Haut et al. 1980). A retrospective
cohort study by Kawasaki (2015) explored this association by evaluating the effects of
increased phosphorus consumption on each nephron. Researchers measured urinary
phosphorus excretion per creatinine clearance and concluded that there was indeed an
association between higher levels of phosphorus excretion per creatinine clearance and
the progression of CKD. This lead to the idea that although phosphorus levels are not
increased during early stages of CKD, high phosphorus consumption results in more
phosphorus to be excreted. This results in higher level of renal tubular damage due to
added burden on each nephron (Kawasaki et al., 2015).

18

Figure 3. Metabolic changes in state of hyperphosphatemia
1) The parathyroid gland releases parathyroid hormone (PTH) in response to
elevated serum phosphorus levels 2) PTH acts on the bones and mobilizes
phosphorus, therefore increasing serum levels 3) PTH stimulates vitamin D
activation in the kidneys and increases phosphorus excretion 4) Released
vitamin D then increases phosphorus reabsorption in the gastrointestinal tract
(GI tract) 5) Fibroblast growth factor 23 (FGF23) is triggered by high
phosphorus, PTH and active vitamin D levels. FGF23 increases phosphorus
excretion and blocks activation of vitamin D leading to decreased levels of
active vitamin D and a subsequent decrease in GI absorption of phosphorus.
More phosphorus in then excreted in the stool 6) Endocrine feedback loop:
Active vitamin D stimulates FGF23 production; FGF23 then serves as a brake
pedal for active vitamin D; PTH stimulates FGF23; FGF23 then shuts off PTH
production.

Results from a retrospective cohort study concluded that phosphate excess is
linked to substantial cardiovascular morbidity and mortality among CKD patients.
19

This occurs independently from identified confounding factors and is thought to be
attributed to the elevated PTH levels, decreased 1,25 (OH)2 vitamin D3 levels and
vascular calcification that results from excessive serum phosphorus levels
(Kestenbaum et al., 2005). In this study by Kestenbaum et al. (2005), researchers
observed a higher mortality risk among participants with serum phosphorus levels in
the high-normal range whereas there was no increase in mortality observed among the
participants with lower serum phosphorus levels.
Although high phosphorus intake is not associated with increased mortality
rates in moderate kidney disease (Murtaugh et al., 2012), it does increase the rate at
which the nephrons deteriorate leading to advanced kidney disease. A cohort study
reported similar finding on the deteriorative effects of phosphorus, suggesting that
higher dietary phosphorus and phosphorus to protein ratios are linked to increased
mortality in hemodialysis patients (Nazanin Noori, Kamyar Kalantar-Zadeh, Csaba P.
Kovesdy, Rachelle Bross, Debbie Benner, 2010). Summarizing these studies it
becomes evident that mortality due to high phosphorus intake increases as GFR
decreases. Ultimately, there is a positive correlation between increased phosphorus
intake and rate of progression of CKD due to the high burden put on the nephrons by
the increased phosphorus intake.
Fibroblast growth factor 23, klotho and CVD in CKD population
Studies have shown patients with CKD have decreased expression α-klotho
(Noritoshi Koh, Toshihiko Fujimori, Shuhei Nishiguchi, Akihiro Tamori, Susumu
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Shiomi, Tatsuya Nakatani, Kazunobu Sugimura, Taketoshi Kishimoto, Satoko
Kinoshitaa, Tetsuo Kuroki, 2001). Results from a study by Koh et al. (2001) suggest
that the decreased expression of α-Klotho in chronic renal failure kidneys is linked to
the morphological loss of nephrons seen in the progression of CKD. These alterations
result in lower amounts of α-klotho expressing cells in the kidneys as well as the
functional deterioration of tubule cells leading to decreased expression of the klotho
gene (Noritoshi Koh, Toshihiko Fujimori, Shuhei Nishiguchi, Akihiro Tamori,
Susumu Shiomi, Tatsuya Nakatani, Kazunobu Sugimura, Taketoshi Kishimoto,
Satoko Kinoshitaa, Tetsuo Kuroki, 2001). As CKD progresses and the expression of
α-klotho is decreased, the function of FGF23 is practically abolished, leading to the
imbalance in bone mineral metabolism (Figure #).
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Figure 4. Metabolic changes when kidney tissue is decreased or absent
1) Little to no kidney tissue leads to decreased vitamin D activation 2)
decreased levels of vitamin D then cause a decrease in calcium absorption,
leading to hypocalcemia 3) hypocalcemia will then act on the bone, mobilizing
both calcium and phosphorus 4) taking the kidneys out of the cycle, the
counterbalance it provided is now ineffective, leading to persistent
hyperphosphatemia 5) this hyperphosphatemia will stimulate PTH production
and indirectly call for more FGF23 production 6) FGF23 attempts to get rid of
the excess phosphorus thru the urine, but since the kidneys are not viable, this
is no longer possible, resulting in persistent FGF23 production 7)
Unfortunately, the FGF23 endocrine feedback loop that will normally shut off
PTH production is ineffective due to Klotho deficiency
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There is a notable increase in risk for cardiovascular disease (CVD) mortality
and morbidity in the CKD population (United States Renal Data System, 2018;
Yamada & Giachelli, 2016). This population is far more likely to die of CVD than to
reach ESRD (Kuro-O, 2011; United States Renal Data System, 2018).

The

mechanisms involved in the development of CVD within CKD patients goes beyond
the traditional risk factors (Yamada & Giachelli, 2016). Novel cardiovascular risk
factors include klotho and FGF23. Alpha-Klotho is a gene that acts as a regulator of
metabolic processes in the body. Two paralogs of α-klotho have been identified (βklotho and γ-klotho), yet for the purpose of this paper we will focus on the effects of
α-klotho, and hereinafter refer to it as klotho (Lu & Hu, 2016). Klotho gene is found in
several organs, but in relation to CKD it is primarily expressed in the kidneys and to a
lesser extent in the parathyroid gland and brain (Kuro-o et al., 1997; Lu & Hu, 2016).
There are two types of klotho derived from the kL gene, membrane-bound klotho and
soluble klotho. There are also two sub-types of soluble klotho, shed and secreted. Shed
soluble klotho is derived from the shedding of membrane-bound klotho by ADAM10
and ADAM17 proteases while secreted soluble klotho is derived from an alternative
splicing of the membrane-bound klotho (Olejnik, Franczak, Krzywonos-Zawadzka,
Kałużna-Oleksy, & Bil-Lula, 2018). The main function of membrane-bound klotho is
to act as a co-receptor for FGF-23, a phosphaturic hormone; whereas soluble klotho is
involved in anti-aging and the regulation of oxidative stress, inflammation and fibrosis
(Olejnik et al., 2018).
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FGF23 is a hormone mainly produced by osteocytes and osteoblast. FGF23
promotes phosphate excretion and inhibits vitamin D activation in the kidneys while
shutting off PTH production, but it requires the presence of klotho. Unfortunately,
klotho levels begin to decline as early as in Stage 1 CKD and continues to decrease as
the disease progresses. As klotho deficiency arises, FGF23 production is increased
with the attempt to normalize phosphorus levels, yet the resulting inhibition of active
vitamin D production reduces klotho expression even further, therefore becoming a
cyclic condition (Kuro-O, 2011).
When the calcium-phosphorus product exceeds the solubility product, it may
contribute to crystal precipitation in the vasculature (Yamada & Giachelli, 2016).
Klotho and FGF23 are also thought to play a key role in vascular calcification. There
is growing evidence gathered from animal experiments that demonstrates that a
decrease in klotho levels can cause vascular calcification, cardiac hypertrophy, cardiac
fibrosis (Lu & Hu, 2016). A study by Chen et al. (2018) examined the mechanism of
phosphate-induced calcification in vascular smooth muscle cells and results suggested
that klotho and FGF23 have the capability of reversing the calcification induced by
high phosphate intake and suppressing phosphate-induced vascular calcification by
inhibiting Wnt7b/β-catenin pathway (Chen, Huang, Duan, Xu, & Chen, 2019).
Patients who undergo dialysis show up to a 30-fold increase in cardiovascular
mortality in comparison to the general population (Yamada & Giachelli, 2016).
Endothelial dysfunction, vascular calcification, oxidative stress and inflammation are
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non-traditional risk factors of CKD individuals that are associated with negative
cardiovascular outcomes. Studies suggest that the elevated levels of FGF23 is
associated with endothelial dysfunction (Yilmaz et al., 2010), and impairment in
endothelium-independent vascular function is significantly higher in CKD population
in comparison to individuals with CVD but preserved kidney function (Kopel et al.,
2017). Researchers concluded that resulting high phosphorus levels speed up the
development of CVD in CKD (Prié, Torres, & Friedlander, 2009). To summarize,
researchers found that that the imbalance of klotho and FGF23 induces increased rate
of progression of CKD and development of CVD in CKD patients. Results suggest
that the manifestation of CVD in CKD may be accelerated due to the
hyperphosphatemia that ensues (Brancaccio, Bellasi, Cozzolino, & Galassi, 2009).
How impact of diabetes and hypertension affect CKD
CKD is a common microvascular complication of uncontrolled diabetes.
Between 25-40% of adults with diabetes develop diabetic nephropathy 20-25 years
after the onset of the disease (Kidney Disease Improving Global Outcomes, 2013).
Diabetes represents the dominant cause leading to end stage renal disease, (Foley &
Collins, 2007) hence the importance of glycemic control in this population to delay or
prevent the microvascular complications of diabetes. The mortality rate for this
population nearly doubles when these complications arise. KDIGO guidelines (2012)
recommend achieving a hemoglobin A1c level of about 7.0% with the purpose of
preventing rapid progression microvascular complications, however, it is also
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important to identify the potential risk for hypoglycemia (low blood sugar levels) that
increases as kidney function declines. Thus, reducing HbA1C further can be
counterproductive. KDIGO emphasized that for CKD individuals with reduced red
cell lifespan, the HbA1C measurement may not be indicative of glucose control and
therefore this biomarker should be interpreted with caution (Kidney Disease
Improving Global Outcomes, 2013).
Hypertension is the second leading cause of ESRD in the US. (Rao, Qiu,
Wang, & Bakris, 2008). Eighty-five to ninety percent of patients with stage 3-5 CKD
suffer from hypertension Aside from being a risk factor for CKD, it also speeds up the
progression of the disease (Segura & Ruilope, 2011). Uncontrolled hypertension
eventually leads to high intraglomerular pressure, affecting the glomerular filtration
rate and causing an increase in protein filtration resulting in a poor prognosis for CKD
and cardiovascular disease. According to the KDIGO guidelines, CKD patients should
target a blood pressure measurement of less than 130/80 mmHg with the goal of
reducing renal and cardiovascular morbidity and mortality. Just as hypertension effects
CKD, CKD also has a negative effect on blood pressure. Due to the damaged blood
vessels in the kidneys, glomerular filtration is lowered resulting in an increase of fluid
volume in the blood leading to hypertension.
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Dietary Guidelines and Nutrition Interventions
Dietary guidelines for chronic kidney disease
The Kidney Disease Outcome Quality Initiative (KDOQI) does not have
precise recommendation for the early stages of Chronic Kidney Disease. However, the
National Kidney Foundation recommends to control the amount of protein, sodium,
potassium and phosphorus to avoid buildup of waste and fluid in the blood as well as
overworking the kidneys. Current recommendations for adult patients with stage 4 or 5
CKD (GFR < 30 mL/min/1.73m2) who are not undergoing dialysis include limiting
protein intake to 0.6-0.8 g/ per kg of body weight and to avoid intakes of >1.3 grams
per kilogram of weight if there is a risk of CKD progression due to proteinuria
(Kidney Disease Improving Global Outcomes, 2013). Scientists have had a difficult
time providing evidence supporting dietary protein restriction in CKD patients due to
lack of patient adherence to low-protein diets. Thus the recommendation for protein
limits dietary intake to a similar level as the recommended dietary intake of protein for
healthy individuals (Kidney Disease Improving Global Outcomes, 2013). Protein
restriction in adults with CKD is thought to help reduce intake of nitrogen, which
would put the patient at lower risk of protein waste build-up in the blood, a condition
often found in advanced CKD patients. Due to the life stage and the importance of
growth at an early age, this protein restriction recommendation only pertains to adults.
Studies exploring the effects of sodium intake (in the form of salt) in CKD
progression suggest that high sodium intake induces an increase in proteinuria as well
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as a potential decrease in glomerular filtration rate, and an increase in blood pressure
(Jones-Burton et al., 2006). Based on this data and the effects of sodium in raising
blood pressure (hypertension), KDIGO guidelines recommend that sodium intake is
lowered to less than 2 grams/day (equivalent to about 5 grams of sodium chloride).
This recommendation, however, may vary based upon the presence of conditions in
which salt restriction may be detrimental as opposed to beneficial. For example, salt
wasting tubular disorders (Kidney Disease Improving Global Outcomes, 2013).
Dietary guidelines for chronic kidney disease - mineral bone disorder
The increased need for medication to control CKD-MBD parameters may be
attributed to the lack of consistency at which this condition is diagnosed. It may also
be attributed to the lack of adherence to dietary recommendations by CKD patients.
Dietary recommendations focused on the management of chronic kidney diseasemineral bone disorder (for non-dialysis patients) are currently not very specific.
Guidelines outline the importance of limiting foods high in sodium, potassium, and
phosphorus as well as the consequences of not maintaining these levels as close to
normal as possible; however, they do not give precise recommendations for the daily
intake of phosphorus and potassium as is the case for protein and sodium (Kidney
Disease Improving Global Outcomes, 2017). Isakova and colleagues (2017) published
a commentary on the 2017 KDIGO Guidelines in which they suggested the daily
intake for phosphorus to be from 0.8-1.0 gram/day and 1 to 2 grams/day for calcium
(from all sources), but again there was no concise recommendation given for intake of
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potassium. Treatment for mineral and bone disorder is aimed at slowing down the loss
of bone (due to renal osteodystrophy) and the elevated amount of minerals deposited
in the blood vessels and heart. Current treatments include diet modifications to balance
dietary intake with existing kidney function, and medications (Beto, Ramirez, &
Bansal, 2014).
Dietary guidelines for CKD and Mineral Bone Disorder at end stage renal disease
When reaching stage five of CKD, many patients undergo renal replacement
therapy (RRT), or dialysis. According to the Academy of Nutrition and Dietetics,
these patients should modify their protein intake to 1.1-1.5 grams/kilogram of weight
due to the amount of protein lost during the RRT process. The bioavailability of the
protein is also important to help patients achieve and maintain adequate serum
albumin levels. Animal protein has a significantly higher bioavailability in comparison
to plant-based proteins, therefore food such as meat, fish, poultry, pork or eggs are
encouraged (Linda M. Ulerich, 2019). Sodium recommendation remains the same,
limited to about 2-3 grams/day to control fluid gain between dialysis treatments.
National Kidney Foundation recommends limiting cured or pickled foods, sauces,
salted snacks such as chips or seeds, luncheon meats, processed food and salt
seasonings, and flavor enhancers that tend to have a high amount of sodium (National
Kidney Foundation, 2019a).
Potassium, calcium, and phosphorus recommendations are more specific once
dialysis has begun. Potassium intake is recommended to stay between 2-4 grams /day
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or 0.4 grams/kg of body weight/day. Foods such as avocados, potatoes, bananas, and
other high potassium foods should be limited, as well as salt substitutes that may
include potassium. Phosphorus is recommended to be between 0.8-1 gram/day to
achieve normal levels. As previously stated, dialysis patients are often encouraged to
increase their animal-based protein due to the increased bioavailability; however, the
bioavailability of phosphorus is also higher in animal-based proteins and this should
be taken into consideration when educating patients on protein and phosphorus
consumption (Moorthi et al., 2014). Bioavailability refers to the degree to which
nutrients are available for absorption and utilization. Other than proteins such as
meats, nuts, beans and dairy products, dark colas and most processed foods are also
high in phosphorus and should be limited or avoided. It is important to check for the
phosphorus content in additives or preservatives, as this inorganic phosphorus is
completely absorbed (Ritz, Hahn, Ketteler, Kuhlmann, & Mann, 2012) The calcium
recommendation is to maintain intake at 2 grams/day from both dietary and
medication sources (Beto et al., 2014). Research suggests that despite the nutrition
counseling provided for this population, the adherence to the diet and fluid
recommendations is fairly poor and is associated to the emotional challenge of making
sense of renal diet information (Beerendrakumar, Ramamoorthy, & Haridasan, 2018;
Lambert, Mansfield, & Mullan, 2018).
Nutrition education intervention for CKD and mineral bone disorder
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Although the etiology of chronic kidney disease is multifactorial, treatment
does not change. The stage of CKD will determine the parameters to be monitored and
will help determine the nutrition intervention needed to delay the progression of the
disease. Pre-dialysis medical nutrition therapy counseling has been shown to delay the
progression of the disease, as well decrease mortality after the first year following
initiation of renal replacement therapy (Beto et al., 2014). The nutrition care process
algorithm from the Academy of Nutrition and Dietetics’ CKD evidence-based
literature recommends patients in stages 3 and 4 visit a registered dietitian every 1-3
months for at least 2 hours/month for up to a year (Beto et al., 2014). The amount of
nutrition education provided needs to be tailored to the individual needs of the
patients.
In a study by Karavetian and Ghaddar (2012), the appropriate amount of
nutrition education provided by a well-trained dietitian can impact the overall clinical
outcomes and help overcome the barriers leading to the lack of adherence to dietary
recommendations often observed in CKD patients. Results from a study by Karavetian
et al. (2016) support these findings highlighting the increased need for tailored
counseling techniques and nutrition education in this population.
Other studies by Karavetian et al. (2014) demonstrated the impact of
increasing the intensity of the protocol used to deliver nutrition education to CKD
dialysis patients on clinical outcomes, such as phosphorus control. They measured
changes by comparing the improvement in overall outcomes preceding nutrition
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education at different degrees of intensity, therefore emphasizing the need for
dedicated dietitians as well as stage-based education for this population (Karavetian et
al, 2014). Some researchers incorporated the use of questionnaires to assess patient
knowledge and quality of life following a structured nutrition education program and
also found that a more structured and intense nutrition education program was the
most effective in improving patient knowledge and quality of life. With the use
validated questionnaires, researchers found that the mean score of patients’ knowledge
and quality of life in the experimental group receiving intense nutrition education had
a significant improvement (Ebrahimi et al., 2016). An important factor to consider
when delivering nutrition education is that limited health literacy can impact the
quality of life and overall clinical outcomes of ESRD patients (Cavanaugh et al.,
2010).
A large percentage of current studies on nutrition education for CKD-BMD
focus on the adherence to low phosphorus diets because findings show that
hemodialysis patients are less likely to follow phosphorus modifications than
potassium and sodium modifications. A study by Duff and Chawke (2017) found that
providing information in regards to possible complications of elevated phosphorus
when delivering phosphorus focused nutrition education had a significant impact on
phosphate levels and patient knowledge (test scores improved by 10%).
Balancing protein and phosphorus intake can be a challenge for CKD patients
whether they are using hemodialysis or not. Shifting from a diet consisting mainly of
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animal protein to a diet consisting of 70% proteins from plants is an efficient way to
lower phosphorus excretion while maintaining optimal dietary intake of protein
(Moorthi et al., 2014). Phosphorus in plant-based products is bound to a compound
called phytate. Humans lack the enzyme to break down phytate bond phosphorus,
leading to low absorption and bioavailability of phosphorus from plant-based sources.
Nevertheless, longer observation periods are needed to get a well-rounded
understanding of the potential benefits of increased amount of plant-based products on
mineral metabolism and cardiovascular complications observed in CKD patients.
Kidney friendly diets- Is it time to re-evaluate?
Whether the current renal diet is effective at providing optimal nutritional
status that will not only protect the kidneys but also the heart, is in question.
Considering that that an overwhelming percentage of the CKD population dies prior to
reaching ESRD due to unforeseen cardiovascular events (Kuro-O, 2011; United States
Renal Data System, 2018), this should be an area of focus when dealing with CKD
patients regardless of the stage. As previously mentioned, studies suggest that
phosphorus may play a role in the manifestation of cardiovascular complications in
early stages of CKD despite the normal serum levels, however there is a lack of
nutrition focused long-term outcome research to prove this relationship. There are
numerous diets with the potential to be effective at delaying the progression of CKD,
such as the Mediterranean Diet (De Lorenzo et al., 2010; Smyth et al., 2016) or
Dietary Approaches to Stop Hypertension (DASH) diet (Smyth et al., 2016; Tyson et
33

al., 2016). Although, these diets provide promising results in early stages of CKD
when certain micronutrients are not restricted, they are ineffective when patients reach
kidney failure. Thus, modifying these diets to decrease the phosphorus load on
nephrons at early stages may amplify its potential to delay the disease.
Another aspect of the renal diet currently gaining popularity is its effect on the
gut microbiota. Current CKD guidelines do not support a healthy microbiota but tends
to support a state of symbiosis that leads to overgrowth of bacteria resulting in the
formation of additional uremic toxins (Hasegawa, Jao, & Inagi, 2017; Mohanty,
Misra, Mohapatra, & Sahu, 2018). Pairing this with the oxidative stress caused by this
state of uremia, not only causes a cyclic relation injuring the kidney even further but it
contributes to the endothelial dysfunction and vascular calcification that arises early in
the progression of CKD.
Rather than focusing on potential benefits of specific nutrients, upcoming
studies should attempt to create a wholesome diet including various novel aspects
currently being studied.

For example, include gut health in relation to

probiotics/prebiotics (Mohanty et al., 2018), antioxidant and anti-inflammatory
properties, differences in metabolites of specific types of macronutrient metabolism
(ex: saturated vs. unsaturated fatty acids) (Hasegawa et al., 2017) while providing not
only nutritional but psychological support. Due to the expected intensity and difficulty
maintaining adherence, trials should be conducted in a well-controlled setting and
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patients ability and desire to adhere should be considered, since this currently
represents the biggest barrier to achieving optimal results.
Perceived Barriers for Achieving Improved Clinical Outcomes
Barriers experienced by renal patients
Despite the number of barriers experienced by both renal patients and renal
practitioners, the literature agrees upon the importance of patient education and its
impact in clinical outcomes (Narva, Norton, & Boulware, 2016). Many people
suffering with chronic kidney disease have low awareness of their health status and
may interpret this as a consequence of limited availability of CKD information.
According to data from NHANES 1999-2012, the overall awareness of disease status
among individuals suffering from CKD is 6.4% (Narva et al., 2016).Unfortunately,
many CKD patients lack motivation and readiness to learn, and their limited health
literacy only complicates this further (Narva et al., 2016; Umeukeje et al., 2015).
Findings indicate that low self-motivation is associated with low adherence to
treatment regimen, but unfortunately, there is scarce research on ways to overcome
emotional barriers associate with progression to ESRD (Umeukeje et al., 2015).
Studies exploring the benefits of peer support suggest that both patients and care
givers find peer support helpful, giving them a sense of control and empowerment,
reducing the uncertainty of the progression of the disease, and making them feel
understood, accepted and less isolated (Taylor, Gutteridge, & Willis, 2015).
Experiencing poor continuity of care, not feeling well and having trouble with dietary
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and fluid restrictions are also common patient barriers in the treatment of CKD (Lo et
al., 2017).
Barriers experienced by renal practitioners
Healthcare providers also have barriers to overcome to effectively treat CKD.
Some of the reported barriers include lack of time with patients, difficulty evaluating
public awareness, lack of knowledge in at risk population and patients’ low literacy
levels (Narva et al., 2016). Dietitians report a lack time to give hemodialysis patients a
well-rounded education that focuses on improving their knowledge and therefore their
adherence to recommendations (Hand & Burrowes, 2015; Stevenson, Tong, Campbell,
Craig, & Lee, 2018). Research states that nephrologists also report not having
adequate time to properly prepare patients for dialysis or build a relationship with
them which makes it more difficult to explain the mechanism of the disease and assess
patient knowledge. Many primary care doctors (non-kidney specialist) report to lack
confidence in their skills to diagnose, treat and explain CKD to patients (Greer et al.,
2015). Lack of education about CKD prior to referral to nephrologist accompanied by
late referral from the primary care doctor contribute to the lack of patients’ acceptance
and trust, as well as the developed fear of dialysis (Greer et al., 2015).
Future Directions
Depression is a frequent comorbidity most often observed among patients in
end stage renal disease. There is little evidence on the efficacy of screening tools for
depression among this population, therefore despite its elevated prevalence, it is often
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overseen (Farrokhi, Beanlands, Logan, Kurdyak, & Jassal, 2017). Research suggests
that patient barriers to seek treatment include concern of possible side effects of
medications, adding more medications to their already overwhelming regimen,
inaccurate perception of severity of problem, risk for depression, and distrust in the
efficacy of treatment (Farrokhi et al., 2017). This population may have a negative way
of coping, and this decreases adherence to treatment (Farrokhi et al., 2017) .
Multidisciplinary team approach can facilitate the delivery of nutrition
interventions, but the disjointed advice that is often given across disciplines is leading
to further confusion in patients. Nutritional issues are being addressed differently
between disciplines due to the conflicting guidelines or providing advice based on outof-date literature or inconclusive research. This results in distrust in the efficacy of
nutritional treatment (Stevenson et al., 2018). Nephrologists and nurses reported to
address nutritional problems for the purpose at hand, meaning that they handle the
issue once a complication arises. Dietitians adopt gradual methods of counseling
providing individualized support to manage nutritional issues before any medical
complications arise (Stevenson et al., 2018). A study on the multidisciplinary team
approach found that an integrated action plan was associated with slower decline in
GFR over time and decreasing number of patients starting dialysis (Bayliss,
Bhardwaja, Ross, Beck, & Lanese, 2011).There is limited research on the use of
standardized multidisciplinary approach in the treatment of CKD with implementation
of psychological testing to screen for depression, considering the significant effects it
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can have on motivation, adherence and overall clinical outcomes (Farrokhi et al.,
2017; Taylor, Taylor, Baharani, Nicholas, & Combes, 2016).
Another area in need of further research is the impact of magnesium in clinical
outcomes of patients undergoing dialysis. Hypomagnesemia is a common condition
among CKD patients due to tubular injuries that lead to magnesium wasting (Oka et
al., 2018). Research suggest that lower serum magnesium is a significant predictor of
mortality among dialysis patients independent of cardiovascular status and increasing
dialysate magnesium has been associate with decreased predisposition to calcification
in hemodialysis patients (Oka et al., 2018). Also, the consumption of proton pump
inhibitors, a commonly used medication among renal patients for gastroesophageal
reflux disease, has been linked to decreased levels of magnesium among CKD
population (Alhosaini et al., 2014; Hughes, Chiu, Kalra, & Green, 2018). Intervention
studies are needed to explore toxicities associated with magnesium supplementation
and to test for optimal strategy for restoration of this electrolyte imbalance.
Summary
According to the United States Renal Data System (USRDS) Annual Report,
the prevalence of CKD has increased from 14.2% (NHANES 2001-2004) to 14.8%
(NHANES 2013-2016); and the prevalence of ESRD has continued to rise about
20,000 cases per year since 2016 (United States Renal Data System, 2018). This
increase can be attributed to increased rates of uncontrolled diabetes and hypertension
in our population. The epidemic of chronic kidney disease is associated with higher
38

mortality rates, thus tailored interventions to delay or stop the progression of the
disease are of critical need. The progression of CKD is gradual and although changes
in bone mineral biomarkers are not observed until later stages of the disease, early
intervention can result in delayed progression. Current nutrition education studies have
demonstrated the efficacy of structured and intense nutrition education programs in
CKD patient's clinical outcomes, yet there is a lack of work demonstrating the impact
of an integrated interdisciplinary approach to nutrition intervention for CKD patients,
particularly those undergoing dialysis.
It is of importance to determine the current barriers experienced not only by
dietitians and patients but by other renal practitioners in the effort to manage CKD and
CKD-MBD through nutrition interventions. Although dietitians are the experts in the
field and should be the ones leading the delivery nutrition intervention programs, other
members of the renal department should also be well educated in need for dietary
modifications and consequences related to poor adherence in order to provide efficient
education and accurate information when the time is appropriate. Information
delivered should be based on updated evidence-based guidelines. There is a need for
ongoing nutrition educational programs for employees from various disciplines
dealing with this population to improve the delivery and consistency of nutritional
advice across all disciplines.
Despite the favorable outcomes reported in some studies in the literature,
mortality rates for CKD have yet to improve. The study hypothesis is that this lack of
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improvement is in fact related to the lack of cardiovascular protection provided by the
current guidelines and this may be attributed to the lack of optimal nutrient intake,
including antioxidant, probiotics/prebiotics and anti-inflammatory food items. The
current study was designed to identify the top barriers experienced by renal
practitioners. Additionally, the study aimed to identify the most frequently used tools
when providing nutrition education to CKD hemodialysis patients. Furthermore, the
study seeks to understand specific nutrients being targeted and determine the average
amount of time that is currently being devoted to nutrition education in a hemodialysis
setting across disciplines.
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Introduction
The obesity pandemic has brought an increased prevalence of chronic diseases,
such as type II diabetes mellitus, hypertension, and chronic kidney disease (CKD)
(Hruby & Hu, 2015; Hossain, Kawar, & El Nahas, 2007; Hurt, Kulisek, Buchanan, &
McClave, 2010; Mitchell, Catenacci, Wyatt, & Hill, 2011). Kidney disease, which
represents the ninth leading cause of death in the US (Xu et al., 2018), is a
degenerative condition characterized by a gradual decline in kidney function and
structural changes; it is classified as CKD when these abnormalities persist for longer
than three months, (Kidney Disease Improving Global Outcomes, 2013). CKD is
asymptomatic, thus early screening and detection, as well as adherence to prescribed
interventions are crucial (National Kidney Foundation, 2019b). Current nutritional
guidelines for the CKD are focused on improving the state of uremia observed in this
population, however they are not effective at providing the cardiovascular protection
this population is in desperate need for as guidelines focus more on restrictions of
specific nutrients as opposed to the potential impact of quality over quantity of
nutrient intake.
The intervention prescribed following a CKD diagnosis depends on the
severity of the disease at the time of detection but it generally includes diet
modification, prescription of pharmaceuticals and at later stages, dialysis or kidney
transplantation. Regardless of etiology, the loss of kidney function in CKD disrupts
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homeostasis in the body. The albumin creatinine ratio (ACR) and the eGFR are
mechanisms used to grade the stage of CKD. ACR varies among the stages of CKD.
Estimated GFR is a measure used to describe the flow rate of filtered fluid through the
kidney (Table 1). When the eGFR is less than 60 mL/min/1.73 m2, certain disruptions
in homeostasis begin to occur. Phosphorus retention occurs due to reduced urinary
phosphorus excretion resulting in decreases in serum calcium levels. PTH attempts to
restore calcium homeostasis by mobilizing calcium from bone and stimulating renal
tubule reabsorption of calcium. PTH also decreases renal phosphorus reabsorption and
increases excretion. Thus, serum calcium and phosphorus return to normal at the
expense of a higher serum PTH. With every decrease in eGFR, the process repeats
itself. Eventually the eGFR gets so low that hyperphosphatemia and hypocalcemia
ensue while PTH continues to rise (Martin & Gonzalez, 2007).
Further damage to the bone is caused by a decreased synthesis of 1,25(OH)2
vitamin D3, increased serum phosphorus. The metabolic acidosis that develops due to
the failing kidneys contribute to the weakening of the bones. Thus, the combination of
bone reabsorption from too much PTH, the buffering of hydrogen ions, and the
decreased bone formation due to low 1,25(OH)2

vitamin D3, results in the

development of renal osteodystrophy, the bone malformation aspect of CKD-MBD
(Martin & Gonzalez, 2007).
It is known that when calcium-phosphorus product exceeds the solubility
product, it may contribute to crystal precipitation in the vasculature (Yamada &
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Giachelli, 2016). However, klotho and FGF23 are also thought to play a key role in
vascular calcification. There is growing evidence gathered from animal experiments
that demonstrates that a decrease in klotho levels can cause vascular calcification,
cardiac hypertrophy, cardiac fibrosis (Lu & Hu, 2016). A study by Chen et al. (2018)
examined the mechanism of phosphate-induced calcification in vascular smooth
muscle cells and results suggested that klotho and FGF23 have the capability of
reversing the calcification induced by high phosphate intake and suppressing
phosphate-induced vascular calcification by inhibiting Wnt7b/β-catenin pathway
(Chen et al., 2019). The changes in metabolic pathways of bone minerals, the
interruption in calcium and phosphate homeostasis, and the vascular calcification
observed in CKD patients in relation to these alterations are collectively known as
chronic kidney disease-mineral bone disorder (CKD-MBD) (Kidney Disease
Improving Global Outcomes, 2017)
Mineral and bone disorders are an inevitable consequence of CKD. While
many approaches are taken to treat CKD-MBD, no data currently exists stating its
exact prevalence. Research has shown that intervention in the form of intense nutrition
education can significantly improve clinical outcomes as well as improve quality of
life (Duff & Chawke, 2017; Ebrahimi et al., 2016; Karavetian et al., 2015, 2016).
Specific Aims
The focus of this study is to distinguish between the different strategies used to
treat Chronic Kidney Disease- Mineral Bone Disorder, the perceptions across
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disciplines and barriers to maintaining mineral homeostasis during dialysis. The
specific aims for this study are: to explore the current barriers perceived by renal
practitioners at dialysis units when addressing the imbalance of minerals that
manifests as a result of CKD; to identify the nutrition education techniques that are
used most frequently in dialysis units and the main concepts discussed in reference to
bone mineral metabolism; and to understand what specific nutrients healthcare
practitioners target when providing nutrition education to manage CKD-MBD.
Methods
Study Design
This was a descriptive study using the survey method. This study was
conducted from February 5th, 2019 to March 21st, 2019. Surveys were distributed to
250 randomly chosen inpatient and outpatient hemodialysis centers in the continental
United States. The study was reviewed by the institutional review board at Winthrop
University and informed consent was provided prior to the start of the survey by
selecting “I agree” on the electronic survey. None of the participants who opened the
survey refused to give consent.
Participants and Setting
The participants included in the study were defined as health care practitioners
with a registered credential, including any relevant heath care professionals involved
in inpatient or outpatient hemodialysis care such as Registered Dietitians, Registered
Nurses and Certified Nurse Assistants. In order to maintain confidentiality, certain
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demographic characteristics were not obtained. Participants were recruited using the
convenience random sampling. Using the USDialysisFinder.com website, a list of
6,027 dialysis centers located in the continental United States were identified, and two
hundred and fifty were randomly chosen to be contacted. If the facility agreed to
participate, an email was sent containing the link to the electronic survey. Due to low
response rate, dietitians were identified through the Renal Practice Group affiliated
with the Academy of Nutrition and Dietetics and a blast email was sent to all renal
dietitians whose information was available to the public. The state chapters of
Academy of Nutrition and Dietetics were also contacted for additional disbursement.
Tools and Instruments
The tool used to gather information was an electronic survey. The questions
were designed to provide the following information specific to Chronic Kidney
Disease-Mineral and Bone Disorder: how much time is spent with patients working on
nutrition education, what nutrients are being targeted during nutrition education,
specific nutrition education tools used and current barriers regarding compliance. The
survey was reviewed by a renal dietitian from Fort Mill Fresenius Medical Center and
the Human Nutrition Program Director at Winthrop University for content validity.
The software Qualtrics was used to develop and distribute the survey.
Procedures
Once the clinics agreed to participate in the study, the link to the survey was
sent to the participants via email. The potential participants from the Renal Practice
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Group were provide with a short introduction in the e-mail that resembled the
information from the script followed for the calls to invite them to participate in the
graduate thesis project. After providing their consent, participants completed the 18question survey via Qualtrics.
Statistical Analysis
The study included 76 participants in the renal field, from the continental
United States. Of the 76 participants, one was excluded due to participating in the pilot
study conducted. Although all participants worked in the renal field, six participants
were excluded from the study due to not working with hemodialysis patients. As a
result, a total of 68 participants were included in the statistical analysis. Statistical
tests, such as chi-square, failed to provide significant results and therefore the
descriptive statistics were presented using proportions and graphical methods.
Descriptive data was analyzed using the statistical software Minitab and the Microsoft
Excel was used to create visual representation of the responses.
Results
Participant and Patient Characteristics
The sample included Registered Dietitians (n=63), Registered Nurses (n=3)
and Certified Nurse Assistants (n=2) (Table 3) with 0.5-35 years of experience in the
renal field (Figure 3). Their work setting was defined as either in-patient (n=11), outpatient (n=49) or a mixture of both (n=8), and their location was broken down into two
region: West (n=15) and East (n=53) (Table 3).
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Table 3. Sample demographics
Registered
Dietitian
63

Registered Nurse
3

Certified Nurse
Assistant
2

11.04 +/- 8.26

11 +/- 1.41

4.67 +/-

N= 48 (76.2%)

N= 3 (100%)

N= 2 (100%)

N= 15 (23.8%)

N= 0 (0%)

N= 0 (0%)

N= 7

N= 3 (100%)

N=1 (50%)

Out-patient Setting

N= 48

N= 0 (0%)

N=1 (50%)

Both (In/Out Patient)

N= 8

N= 0 (0%)

N= 0 (0%)

N=
Mean Longevity (yrs.
+/- SD)
Eastern U.S.
Location
Western U.S.
Location
In-patient Setting

*Appendix C: Classifies East vs. West U.S. Regions
Participants were asked to give an estimate of the age range in which most of
their patients fall in as well as an approximate percentage of their racial breakdown.
Results indicate that the vast majority of patients are ≥ 40 years old (n=64) (Table 4)
and most are either White Caucasian (mean 40.28 +/- 24.24) or African American
(mean 42.30 +/- 27.93).

Patient Age Range

N=

0-18 years old

2 (3%)

20-40 years old

2 (3%)

40-60 years old

32 (47%)

>60 years old

32 (47%)

Table 4. Breakdown of patient age
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Nutrition Education
Participants were asked the amount of years that they have been working in
direct patient care of CKD clientele, average age range of CKD patients, average
percentage of CKD patients receiving nutrition education specific to CKD, average
amount of time spend on nutrition education with each patient per visit and at what
stage of CKD do they believe to be the most critical to begin nutrition intervention to
effectively treat CKD-MBD. Graphics were used to give a visual break down of the
data.

Figure 5. Number of years working in direct care of CKD clientele
*Percent is calculated within all data
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[VALUE]%
70
60
50
20.63

40
42%

30

[VALUE]%

20
10
0
>75%

50-75%

25-50%

<25%

Figure 6. Percentage of renal patients receiving nutrition education
specific to CKD
*Percent is calculated within all data

42%
[VALUE]%
40
35
30
25
[VALUE]%

20

[VALUE]%
[VALUE]%

15
10
5
0
0-10 minutes

10-20 minutes

20-30 minutes

30-40 minutes

≥50 minutes

Figure 7. Average amount of time spent on nutrition education with each
patient per visit
*Percent is calculated within all data
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Participants were also asked to rank the three most important tools used to aid
in nutrition education and three most important micro- and macro-nutrients when
educating CKD patients. Graphics were used to summarize the results.

Group
education
6%%

One-on-one
education
30%

Videos
7%
Pamphlets
11%

Handouts
28%
Visual Aids
18%

Figure 8. Tools ranked as one of the three most important used in nutrition
education
*Percent is calculated within all data
43%
37%
32%
24%
19%

26%
21%
16%

15%

1%
Phosphorus

Potassium
Ranked #1

Sodium
Ranked #2

4% 4%

Calcium

Ranked #3

Figure 9. Three most important micronutrients for CKD nutrition education
*Percent is calculated within all data
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57%
49%

34%
26%
22%

21%

10%

7%

7%
3%

Protein

Fluids
Ranked #1

Calories
Ranked #2

9%
4%

Nutrient Density

Ranked #3

Figure 10. Three most important macronutrients for CKD nutrition education
*Percent is calculated within all data

Barriers in managing CKD in hemodialysis patients
It is important to keep in mind that the barriers to compliance assessed were
identified from the renal practitioner’s perspective rather than patient perspective. To
assess common beliefs around nutrition education and CKD-MBD, there was a
question on whether or not they believe that nutrition education is an effective method
of treatment and, if so, what stage they found to be most critical to implement the
nutrition intervention. The results showed that only one out of 68 participants did not
find nutrition education to be an effective methods and close to half (n=33) of the
participants believe that nutrition should be initiated at early stages (stage one or two)
versus late stages (stages three-five) (n=35).
52

28%
24%
21%

22%
21%
16%

13%
12%

15%

13%

9%

9%
7%

9%

10%

7%
3%

1%
Lack of
Family/Friend
Support

Cost

Medication
Compliance
Ranked #1

Dietary
Compliance

Ranked #2

Lack of
Not Enough Time
Understanding of
Educating
Renal Diet
Patients

Ranked #3

Figure 11. Barriers in managing CKD in hemodialysis patients
*Percent is calculated within all data

Discussion
The findings of this study suggest that there is a lack of focus on the quality
over the quantity of nutrients when providing nutrition education. This may lead to
suboptimal nutrient intake in a large portion of the CKD population. When asked to
rank macronutrient topics in order of importance, nutrient density was not chosen as
one of the top three most important macronutrient topics. Despite efforts to improve
CKD patients’ quality of life, the results of this lack of focus on the nutrient density
translates into the negative outcomes commonly observed in relation to cardiovascular
health and subsequent mortality rates. Not every recommendation is quantifiable when
dealing with CKD patients.
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Findings from other studies have demonstrated a positive impact on clinical
outcomes by increasing the intensity of the protocol used to deliver nutrition education
to CKD dialysis patients (Karavetian et al., 2016). Yet dietitians have reported a lack
of time to give patients a well-rounded education that focuses on improving
knowledge and adherence to recommendation (Hand & Burrowes, 2015). This study’s
results support previous findings by showing that the vast majority of dietitian in
hemodialysis units spend (N=52) only from 0-20 minutes giving nutrition education to
each patient per visit, in spite of renal practitioners reporting that >75% of their
patients receive nutrition education specific to CKD. There was not a significant
difference reported between in-patient and out-patient setting, or between the West
and East region of U.S when it came to the time spent educating patients. Taking into
account the limited patient awareness, low literacy rates, and lack of education prior to
advanced stages of CKD that has been reported by previous data, the reported time
frame seems insufficient. Another aspect to consider is that a reported 94% of patients
are older than 40 years old, which can sometimes make it more difficult for change to
occur. Although findings from this study did not identify “not enough time educating
patients” as a top barrier in managing CKD in hemodialysis units, it was ranked as
number one barrier by nine percent of participants, following the barriers of cost,
medication compliance, and dietary compliance, making it a significant challenge
when trying to improve overall patient outcomes.
To my knowledge, there are no studies exploring at which stage renal
practitioners consider to be most critical to initiate nutrition education. Interestingly,
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results from this data showed that about half of the participants considered early stages
(stages 1 and 2), with the other half considering late stages (stages 3 to 5) to be the
most critical for initiation of nutrition intervention.
Aside from the need for further research on ways to detect and treat CKD more
effectively at earlier stages of the disease, the comorbidity of depression should also
be given closer attention. Further research should study how a multidisciplinary
approach, including implementation of improved psychological testing to screen for
depression could impact the mortality rate of dialysis patients.
Conclusion
Although dialysis is meant to hold the role of an “artificial kidney”, it is not as
effective at removing waste products as are the kidney when in a healthy state. When
paired with an appropriate diet, medications and patient compliance, patient outcomes
have shown to improve. However, the overall mortality rate and cardiovascular
complications often experienced by this population have not gotten better, and this
may be attributed to lack of concentration in the quality of the recommended diet.
Current guidelines are targeting the state of uremia in dialysis patients and quantity of
nutrient intake is given more importance than the actual quality, leading to a harmful
state for these patients’ cardiovascular system. This study identified cost, medication
and dietary compliance as the top barriers for managing CKD and concluded that oneon-one education is the most effective tool used in nutrition intervention. Participants
consider phosphorus, potassium and sodium to be the most important micronutrients
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for CKD dialysis patients, yet if the focus was given to the overall quality of the diet,
phosphorus and sodium would not be micronutrients of concerns. Dietary
recommendation for this population should be individualized taking into consideration
the etiology of each patient’s kidney condition. This will require more time devoted to
patient knowledge, tailored dietary interventions and an interdisciplinary approach
including the help of a mental health professional. As complex as CKD can get, the
regimen has to be just as aggressive.
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Chronic Kidney Disease-Renal Osteodystrophy
Daniela Gutierrez

FACULTY ADVISOR:

Hope Lima
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EXEMPTION CATEGORY:

14(b) Research involving the use of educational tests (cognitive, diagnostic, aptitude,
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(a) information obtained is recorded in such a manner that human subjects can be identified,
directly or through identifiers linked to the subjects; and (b) any disclosure of the human
subjects’ responses outside the research could reasonably place the subject at risk of criminal or
civil liability or be damaging to the subjects’ financial standing , employability or reputation.
[45CFR46(b)(2)]
Research involving children (subjects who have not attained the age of 18 years) is not exempt
unless the research involves only the observation of public behavior and the researchers do not
participate or impact the activities being observed. [45CFR46.401(b)]
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or a change in the Researcher of Record.
Use the form Adverse Event Report to report any negative consequences that occur as a result of participation in a
research project. . An “adverse event” or “adverse experience” is an undesirable and unintended, though not necessarily
unanticipated, injury or physical or emotional consequence to a human subject. “Unanticipated Problems” may or may not
include specific events experienced by individual subjects, but are developments within the research activity that suggest a
potential for increased risks to subjects or others.
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Winthrop University Institutional Review Board
803-323-4654
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Sample Email:
Subject: Chronic Kidney Disease-Mineral Bone Disorder Survey
To Whom It May Concern:
Thank you for your interest in participating in our research study looking at nutrition
education for chronic kidney disease- mineral bone disorder (CKD-MBD). The purpose
of this study is to look at the current standards of care in place to treat the progression
of CKD-MBD with nutrition education. We would greatly appreciate if you took 10-15
minutes of your time to complete our electronic survey. This survey is intended to get
insight of the perspective of renal healthcare practitioners such as registered dietitian,
nurse, medical doctor, social worker and /or any relevant health care professional
involved in outpatient and inpatient hemodialysis patient care. Your participation is
voluntary and will remain confidential. The information gathered will help to determine if
further research in the treatment of CKD-MBD with nutrition intervention is necessary. If
you decide to participate in this research and change your mind, you may withdraw at
any time.
If you have any questions about the research study, please contact Daniela Gutierrez
by email: delgadod2@winthrop.edu, or by phone: 704-925-5396.
Dr. Hope Lima supervises this research. You can reach Dr. Lima by email:
limah@winthrop.edu or by phone: 803-323-4553 for further questions.
Please click the following link to access the survey:
https://winthropstudents.qualtrics.com/jfe/form/SV_bNGByd8lYiC8Tad
Thank you so much for your participation.
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Informed Consent attached to survey:
Chronic Kidney Disease-Mineral Bone Disorder Survey
The purpose of this study is to look at the current standards of care in place to treat the
progression of Chronic Kidney Disease-Mineral Bone Disorder with nutrition education
and intervention. We would greatly appreciate if you took 10-15 minutes of your time to
complete our electronic survey. Your participation is completely voluntary and will
remain confidential. All electronic data will be stored on a USB drive and all paper
documents containing data will be safeguarded in an envelope kept in a locked cabinet
in the Dalton room 304, Winthrop University. The electronic data and paper documents
will be destroyed after 3 years or after publication, whichever comes first. To help
protect your identity, the surveys will not personally identify you with your responses
and any identifiers will be erased before the data is analyzed. There is little to no risk in
your participating in this research project. The information gathered will help to
determine further research in the treatment of Chronic Kidney Disease-Mineral Bone
Disorder with nutrition intervention. If you decide to participate in this research, you may
withdraw at any time.
If you have any questions about the research study, please contact Daniela Gutierrez
by email: delgadod2@winthrop.edu, or by phone: 704-925-5396.

Dr. Hope Lima supervises this research. You can reach Dr. Lima by email:
limah@winthrop.edu or by phone: 803-323-4553 for further questions.
By selecting agree you are consenting to participate in this research study.
a. Agree
b. Disagree
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1. Did you participate in the survey development or original pilot study (Renal
Osteodystrophy Survey)?
a. Yes (skip to the end )
b. No
Healthcare Provider Demographics
2. Do you work with hemodialysis patients?
a. Yes
b. No (if no, thank you for your time)
3. In which state of the US do you currently work at?
a. ____________
4. In which setting do you see your patients?
a. Inpatient
b. Outpatient
c. Both
d. Other:_____________
5. What is your role in working with Chronic Kidney Disease patients/clients?
a. Registered Dietitian/Registered Dietitian Nutritionist
b. Renal Nurse
c. Nurse Practitioner
d. Physician Assistant
e. Medical Physician
f. Social Worker
g. Other (please specify) : ________________
6. How long have you been working in direct patient care of Chronic Kidney
Disease clientele?
a. ________________
Chronic Kidney Disease Patients’ Demographics
7. On average, what age range do the majority of your Chronic Kidney Disease
patients fall in?
a. Under 18 years old (skip to the end)
b. 20 – 40 years old
c. 40 – 60 years old
d. More than 60 years old
8. What is the racial breakdown of the chronic kidney disease patients under your
care? (Please provide approximate percentages)
a. White Caucasian ______
b. African American______
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c. American Indian _______
d. Asian_______
e. Hispanic / Latino______
f. Other (please specify: )________
Nutrition Education for Chronic Kidney Disease
9. Do you believe that nutrition intervention is an effective way to manage Chronic
Kidney Disease?
a. Yes
b. No (if no, skip to the end)
10. On average, what percentage of your Chronic Kidney Disease patients receive
nutrition education specific to CKD?
a. 0% (if 0%, skip to the end)
b. less than 25%
c. 25%-50%
d. 50%-75%
e. 75% or more
11. What is the average amount of time that you spend on nutrition education with
each patient per visit?
a. 0-10 minutes
b. 10-20 minutes
c. 20-30 minutes
d. 30-40 minutes
e. 50 minutes or more
12. Please rank the three most important tools you use to aid in your nutrition
education with #1 being the most important.
a. Pamphlets _______
b. Group education _______
c. One-on-one education _______
d. Visual aids _______
e. Videos _______
f. Handouts _______
13. Please rank the three most important micronutrients included in your nutrition
education with Chronic Kidney Disease patients with #1 being the most
important.
a. Sodium _______
b. Potassium _______
c. Phosphorus _______
d. Calcium _______
e. Other (_______________)
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14. Please rank the three most important macronutrients topic included in your
nutrition education with Chronic Kidney Disease patients with #1 being the most
important.
a. Protein _______
b. Fluids _______
c. Calories _______
d. Nutrient Density_______
e. Other (_______________)______
15. Please rank the three biggest barriers in managing Chronic Kidney Disease in
hemodialysis patients with #1 being the biggest barrier.
a. Lack of family/friend support _____
b. Costs _____
c. Medication compliance_____
d. Dietary compliance _____
e. Lack of understanding of nutrition information provided _____
f. Lack of time with patients_____
g. Other (please specify: ______)
16. At what stage of chronic kidney disease do you believe to be the most critical to
begin nutrition intervention in the prevention of Chronic Kidney Disease-Mineral
Bone Disorder?
a. Early stages of chronic kidney disease (Stages 1 & 2)
b. Advanced stages chronic kidney disease (Stages 3 & 4)
c. End stage renal disease (Stage 5)

17. If you have any further comments regarding this topic please comment here.
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Phone Script
“Hello, My name is __________, I am a graduate student in the Human Nutrition
program at Winthrop University in Rock Hill, South Carolina. I was wondering if you had
a few minutes to discuss if your facility would be willing to participate in a graduate
thesis research project.
If YES:
“Great! The purpose of our study is to look at the current standards of care in place to
prevent the development of Chronic Kidney Disease-Mineral Bone Disorder with
nutrition education and intervention. Participating in our study will require you and your
staff to complete a brief survey that will take approximately 10-15 minutes to complete.
Would this be of interest to you?
IF NO:
“Thank you so much for your time, have a wonderful day”.
IF YES:
Great, can you please provide the best email address to send a link to the electronic
survey to be completed along with the information about how your privacy will be
protected (Obtain email).
Thank you. Do you have any questions at this time (Answer any questions). Thank you
so much for your interest in our study and have a wonderful day”.
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Appendix B. Sample Diet
Breakfast


1 medium egg



2 medium egg whites



1 cup steamed spinach



1 slice whole wheat bread



1 cup strawberries

Lunch


3.5 oz. of chicken breast



1 cup whole wheat spaghetti



2 tablespoons of homemade pesto



1 cup cucumber salad with homemade with 1 tbsp. Italian dressing

Dinner


3 oz. New York strip steak with parsley as garnish



½ cup Brussel sprouts



1.5 cup tossed salad with 1 tbsp. of olive oil and 3 lime wedges



1 cup cucumber salad with homemade Italian dressing

Snacks


1 cup Frozen Grapes



¾ cup of Blueberries
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Nutrient Details

Quantity

CALORIES

1411 calories

PROTEIN

87g

FAT

63.13

CARBS

138.23

Omega 3

1.65g

Iron

12mg

Magnesium

225mg

Calcium

354mg

Phosphorus

766mg

Potassium

2500mg

Vitamin D

43 IU

Cholesterol

241mg

Vitamin K

285.6mcg

Sodium

1050mg

*Things to consider: Micronutrient will vary from day to day and you should aim to consume a
varied diet to ensure overall optimal consumption. Clients are not expected to reach all DRI
daily. This diet was intended to fit a 1300-1500 kcal plan. This nutrient analysis only takes into
consideration sodium from the foods and ideally no salt will be added, however, there is room
for variation without exceeding the recommended amount.
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Appendix C. East VS. West U.S. Breakdown

*Originally broken down into 5 regions- only used East vs. West for analysis
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